AXIM Biotechnologies, Inc. (AXIM)
Stock Price:
$0.820 USD
0.010 (1.25%)
Updated Aug 7, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
107.49M |
| Revenue (ttm) |
789,562 |
| Net Income (ttm) |
-6.13M |
| Shares Out |
131.09M |
| EPS (ttm) |
-0.09 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$0.820 |
| Previous Close |
$0.810 |
| Change ($) |
0.010 |
| Change (%) |
1.25% |
| Day's Open |
0.830 |
| Day's Range |
0.800 - 0.830 |
| Day's Volume |
191,513 |
| 52-Week Range |
0.100 - 1.440 |
More Stats
| Market Cap |
107.49M |
| Enterprise Value |
113.34M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
131.09M |
| Float |
84.23M |
| EPS (basic) |
-0.09 |
| EPS (diluted) |
-0.09 |
| FCF / Share |
-0.07 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
-0.41 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
136.14 |
| PB Ratio |
n/a |
| Revenue |
789,562 |
| Operating Income |
-6.06M |
| Net Income |
-6.13M |
| Free Cash Flow |
-5.40M |
| Net Cash |
-5.85M |
| Net Cash / Share |
-0.04 |
| Gross Margin |
28.34% |
| Operating Margin |
-767.47% |
| Profit Margin |
-776.80% |
| FCF Margin |
-684.28% |
| ROA |
-54.36% |
| ROE |
n/a |
| ROIC |
-126.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 0.80 | 0.20 | 0.05 | 0.05 | 0.05 | - | - | 0.04 | 0.01 |
| Revenue Growth | 308.7% | 311.19% | 1.09% | -4.23% | - | - | - | 333.33% | - |
| Gross Profit | 0.22 | 0.19 | - | -0.11 | - | - | - | 0.04 | 0.01 |
| Operating Income | -6.51 | -5.04 | -3.15 | -3.76 | -10.05 | -0.51 | - | -0.01 | - |
| Net Income | -6.45 | -6.75 | -4.17 | -5.81 | -10.09 | -0.58 | -0.09 | -0.01 | - |
| Shares Outstanding | 61.95 | 57.28 | 53.30 | 41.73 | 37.05 | 33.00 | 33.00 | 33.00 | 23.28 |
| Earnings Per Share | -0.10 | -0.12 | -0.08 | -0.17 | -0.27 | -0.02 | - | - | - |
| Operating Cash Flow | -5.02 | -4.85 | -3.08 | -1.29 | -1.54 | -0.34 | -0.03 | 0.02 | - |
| Capital Expenditures | - | - | - | - | -0.02 | - | - | - | - |
| Free Cash Flow | -5.02 | -4.85 | -3.08 | -1.29 | -1.56 | -0.34 | -0.03 | 0.02 | - |
| Cash & Equivalents | 0.76 | 1.96 | 2.06 | 1.22 | 0.14 | 0.67 | 0.00 | 0.02 | 0.02 |
| Total Debt | 6.10 | 5.87 | 6.40 | 1.77 | 1.52 | 1.05 | 0.05 | 0.05 | - |
| Net Cash / Debt | -5.35 | -3.91 | -4.34 | -0.55 | -1.38 | -0.38 | -0.05 | -0.03 | 0.02 |
| Assets | 1.69 | 2.09 | 2.19 | 1.45 | 1.26 | 0.74 | 0.06 | 0.13 | 0.14 |
| Liabilities | 8.45 | 8.17 | 8.48 | 3.82 | 2.96 | 1.32 | 0.15 | 0.14 | 0.13 |
| Book Value | -6.76 | -6.08 | -6.28 | -2.37 | -1.70 | -0.58 | -0.09 | - | 0.01 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
AXIM Biotechnologies, Inc. |
| Country |
United States |
| Employees |
3 |
| CEO |
John W. Huemoeller |
Stock Information
| Ticker Symbol |
AXIM |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: AXIM |
Description
AXIM Biotechnologies, Inc. is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). The company's NeuCovix is the rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. It is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was founded in 2010 and is headquartered in San Diego, California.